

Monday, 5 February 2007

India Morning Meeting Notes



T O D A Y ' S S T O R I E S

Gujarat Ambuja – 4Q06 results update
Ashok Leyland – Earnings upgraded on strong volume
Banks – India – Post-quarterly update (3QFY07)

Mohan Swamy

mohan.swamy@in.abnamro.com

+9122 6715 5304

Company news

Gujarat Ambuja – 4QY06 results update

GAMB maintained the trend of cement sector, by reporting strong operating performance, driven by volumes/prices. Going forward (next two years), we expect GAMB's volume growth to be marginally lower than the industry demand growth, as its capacity ramp up is scheduled for only 2009. We estimate an EPS of Rs9.75/mt in 2007, and we see limited scope for upgrade. GAMB's is relatively more exposed to port-based locations (40% of sales to Gujarat and Maharashtra). While we do not see any impact of the recent import duty cut on pricing, this could be viewed as a potential risk factor by market. The current landed cost to pricing in port cities in the west leaves a gap of 10% (Mumbai) to 17-18% (Gujarat), hence we see no risk to earnings. The stock trades at 14.5x 2007F earnings. Maintain Buy with a target price of Rs153.

GAMP reported 110% EBITDA growth and EBITDA/mt of Rs1,163.

- **Sales:** Growth of 72% yoy, driven volume growth of 20.5% and a realisation growth of 43%. The volumes reflect the merger of Ambuja Eastern Ltd, which now reflects in GAMP's account.
- **EBITDA:** EBITDA growth of 110% to Rs1,163 was better than expected. EBITDA /mt was one of the highest among the larger cement companies, and just a shade lower than the best quarter so far of April-June 2006. Cost/mt at Rs2,063/mt increases from Rs1,958 (September quarter), a 5% rise. However, selling price rose 5.2%.
- **Other income** was higher at Rs4,03m (includes forex gains of Rs165m), hence our PAT numbers were beaten by a wide margin. Tax rate was 26%.
- We estimated a **PAT** of Rs15.4bn (18-month period) vs actual reported of Rs16.6bn (due partly to higher other income).
- We estimate an EPS of Rs9.8 for 2007 and 11.3 for 2008. The stock trades at 14.6x 2007F PE.

Capacity

GAMB is working to increase its capacity from 16mmt to 22mmt by 2009 in phases. This includes a grinding unit in West Bengal (1mmt, likely in April 2007), Rajasthan expansion by 0.5mmt, and a new unit in Himachal Pradesh with grinding units in UP and Haryana (3mmt capacity, expected in June 2009).

Important disclosures and analyst certifications regarding companies can be found in the Disclosure Appendix.

www.abnamroresearch.com

Table 1 : Gujarat Ambuja Cements Limited

(Rs m)	2Q007	3Q07	4Q07	4Q06	Growth
Net sales	11,342.40	9,841.40	13,291.00	7,731.50	72%
Operating expenses	6,909.00	6,285.20	8,500.30	5,453.10	
Change in stocks	28.40	(60.50)	146.70	(15.70)	
Raw materials	690.40	493.00	822.90	423.20	
Staff cost	363.00	408.80	416.20	320.80	
Power and fuel	1,998.40	1,911.80	2,297.70	1,848.50	
Freight & forwarding	2,175.20	1,892.20	2,565.00	1,399.80	
Other expenditure	1,653.60	1,639.90	2,251.80	1,734.40	
Gross profit	4,433.40	3,556.20	4,790.70	2,278.40	110%
Gross margin (%)	39%	36.1%	36.0%	29.5%	22%
Interest	122.90	85.10	44.90	197.20	-77%
Depreciation	496.70	499.50	572.20	501.90	14%
Other income	(99.90)	258.00	402.60	(75.90)	-630%
Pre tax earnings	3,713.90	3,229.60	4,576.20	1,503.40	204%
Tax	675.00	783.00	1,198.60	366.50	227%
Earnings after tax	3,038.90	2,446.60	3,377.60	1,136.90	197%
Net earnings	3,038.90	2,446.60	3,377.60	1,136.90	197%
Provisions				257.90	
PAT			3,377.60	879.00	284%
Qty	3.77	3.21	4.12	3.42	
Average realn(gross)	3,008.59	3,066	3226	2261	
Power & fuel cost		596	558	540	
Total cost	1832.626	1958	2063	1594	
EBITDA/mt	1176.0	1,107.85	1162.8	666.2	

Source: ABN AMRO

Ashok Leyland (AL IN; Rs49.10; Buy) – Earnings upgraded on strong volume

Impressive December 2006 results and strong volume momentum prompt us to upgrade our earnings estimates. However, a high capex plan of Rs40bn leads us to cut our DCF-based target price to Rs57 (from Rs60.20), or 16x our FY08F EPS. We reiterate Buy.

Key forecasts

	FY05A	FY06A	FY07F	FY08F	FY09F
Revenue (Rsm)	41823.8	52476.6	71576.5	80739.5	88995.3
EBITDA (Rsm)	4228.5	5400.7	7268.0▲	8172.3▲	8956.6
Reported net profit (Rsm)	2714.1	3273.2	4413.6▲	4750.9▲	5124.5
Normalised net profit (Rsm) ¹	2544.9	3056.1	4280.0	4750.9	5124.5
Normalised EPS (Rs)	1.91	2.29	3.21▲	3.56▲	3.84
Dividend per share (Rs)	1.00	1.20	1.30	1.60	1.75
Dividend yield (%)	2.07	2.48	2.69	3.31	3.62
Normalised PE (x)	25.3	21.1	15.1▼	13.6▼	12.6
EV/EBITDA (x)	14.2	11.1	8.18	7.82	7.32
Price/book value (x)	5.52	4.56	3.22	2.89	2.60
ROIC (%)	14.1	18.4	21.9	18.2	14.8

1. Post-goodwill amortisation and pre-exceptional items

Accounting Standard: GAAP

Source: Company data, ABN AMRO forecasts

year to Mar, fully diluted

Impressive quarterly results on the back of margin expansion

For the December 2006 quarter, Ashok Leyland (AL) reported a 92% jump in normalised PAT to Rs1.08bn on 48% sales growth, as EBITDA margins expanded by 70bp yoy and 250bp qoq to 10.4%. The effect of price increases and improvement in product mix in favour of higher tonnage led the performance. For 9MFY07, due to a weak September 2006 quarter, AL reported a 46% jump in EPS to Rs1.9 on 39% net sales growth to Rs48.8bn despite 10bp EBITDA margin pressure to 9%.

We upgrade our 2007-08 volume forecasts by 17-19%

On the back of strong volume momentum in the M&HCV sector, AL recorded 38% volume growth for 9MFY07 and maintained 27% market share for the quarter, by sacrificing 10bp in EBITDA margins. Considering the continued buoyancy in M&HCV volumes on the back of strong freight availability and easing fuel prices, we upgrade our volume forecasts by 16.8% to 82,215 vehicles for FY07 and by 19% to 90,845 vehicles for FY08.

Volume growth at cost of EBITDA margins

EBITDA margin expansion was curtailed by high commodity prices and increased competition, despite a strong volume surge. As a result, we expect flattish EBITDA margins compared with our earlier projection of margin expansion. Our EPS upgrades are also restricted to Rs3.2 (12.7%) for FY07F and Rs3.6 (9.0%) for FY08F.

High capex to double capacity affects our target price; Buy, TP Rs57


AL plans Rs40bn capex, spread over the next four years, to double capacity to 200,000 vehicles and for non-organic growth opportunities. We incorporate that expense and our expectations of lower capital output in the initial years of the expanded capacity into our valuation. With that, and despite our earnings upgrade, we reduce our DCF-based target price to Rs57, or 16x our FY08F EPS. We maintain our Buy rating.

Sector

Banks – India – Post-quarterly update (3QFY07)

BOI and Andhra Bank reported the best qualitative operating earnings among public sector banks in our universe while HDFC Bank was the best in our private sector universe. We maintain our Overweight recommendation on the sector.

3QFY07 - Loan growth and net interest income growth (% yoy)



Source: ABN AMRO

Bank of India and Andhra Bank fare the best among public sector banks

Bank of India and Andhra Bank continued to display the best operating parameters among the public sector banks under our coverage. This was partially on the back of moderate loan growth and a focus on operating margins.

HDFC Bank fares the best among private sector banks

Within the private sector, HDFC Bank maintained the best operating parameters among our coverage universe. Moderation of loan growth and the ability to sustain the high proportion of low-cost deposits led to the better-than-peers performance.

RBI increases loan loss provision and risk weighting

In the credit policy announced on 31 January 2007, RBI increased the loan loss provision and capital requirements for specific segments. On our back of the envelope calculations, this should lead to a higher provision charge of 2-5% of pre-provision earnings. However, we believe banks will increase lending rates in these specific segments and hence the impact on earnings should be immaterial.

Maintain Overweight recommendation on the sector

Our top picks in the public sector are Bank of India, Andhra Bank and PNB, while HDFC Bank is our top pick in the private sector.

News headlines**Pharma**

- Dr Reddy's readies to join race for Merck sale (BS)
- Max Healthcare looking beyond NCR for expansion (BL)

Energy

- Anil Ambani sets sights on Globaleq's assets (ET)

Property

- Deutsche bank in advanced discussions to invest around 4200m in Emaar-MGF (ET)
- Emaar-MGF may go public in Q3 (ET)

IT, Telecom, ITES

- Bharti moves DOT against BSNL over call termination rights (ET)
- Genpact plans India's largest IPO in the US to raise \$500-600m (ET)
- Hindujas commence due diligence on Hutch (BL)
- TCS signs pact with Mumbai International Airport to provide consultancy services (BL)

Global disclaimer

© Copyright 2007 ABN AMRO Bank N.V. and affiliated companies ("ABN AMRO"). All rights reserved.

This material was prepared by the ABN AMRO affiliate named on the cover or inside cover page. It is provided for informational purposes only and does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. While based on information believed to be reliable, no guarantee is given that it is accurate or complete. While we endeavour to update on a reasonable basis the information and opinions contained herein, there may be regulatory, compliance or other reasons that prevent us from doing so. The opinions, forecasts, assumptions, estimates, derived valuations and target price(s) contained in this material are as of the date indicated and are subject to change at any time without prior notice. The investments referred to may not be suitable for the specific investment objectives, financial situation or individual needs of recipients and should not be relied upon in substitution for the exercise of independent judgement. The stated price of any securities mentioned herein is as of the date indicated and is not a representation that any transaction can be effected at this price. Neither ABN AMRO nor other persons shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way from the information contained in this material. This material is for the use of intended recipients only and the contents may not be reproduced, redistributed, or copied in whole or in part for any purpose without ABN AMRO's prior express consent. In any jurisdiction in which distribution to private/retail customers would require registration or licensing of the distributor which the distributor does not currently have, this document is intended solely for distribution to professional and institutional investors.

Australia: Any report referring to equity securities is distributed in Australia by ABN AMRO Equities Australia Ltd (ABN 84 002 768 701, AFS Licence 240530), a participant of the ASX Group. Any report referring to fixed income securities is distributed in Australia by ABN AMRO Bank NV (Australia Branch) (ABN 84 079 478 612, AFS Licence 238266). Australian investors should note that this document was prepared for wholesale investors only.

Canada: The securities mentioned in this material are available only in accordance with applicable securities laws and may not be eligible for sale in all jurisdictions. Persons in Canada requiring further information should contact ABN AMRO Incorporated.

Denmark: ABN AMRO Bank N.V. is authorised and regulated in the Netherlands by De Nederlandsche Bank. In addition, ABN AMRO Bank N.V., Copenhagen Branch is subject to local supervision by Finanstilsynet, the Danish Financial Supervisory Authority. ABN AMRO has adopted rules to ensure the integrity and independence of research analysts and the research function, as well as to identify, manage, avoid or make public actual or potential conflicts of interest relating to analysts or ABN AMRO. All analysts located in Denmark follow the recommendations from the Danish Securities Dealers Association.

Finland: ABN AMRO Bank N.V. is authorised and regulated in the Netherlands by De Nederlandsche Bank. In addition, ABN AMRO Bank N.V., Helsinki Branch is subject to local supervision by Rahoitustarkastus, the Finnish Financial Supervision Authority. ABN AMRO has adopted rules to ensure the integrity and independence of research analysts and the research function, as well as to identify, manage, avoid or make public actual or potential conflicts of interest relating to analysts or ABN AMRO.

Hong Kong: This document is being distributed in Hong Kong by, and is attributable to, ABN AMRO Asia Limited which is regulated by the Securities and Futures Commission of Hong Kong.

India: Shares traded on stock exchanges within the Republic of India may only be purchased by different categories of resident Indian investors, Foreign Institutional Investors registered with The Securities and Exchange Board of India ("SEBI") or individuals of Indian national origin resident outside India called Non Resident Indians ("NRIs") and Overseas Corporate Bodies ("OCBs"), predominantly owned by such persons or Persons of Indian Origin (PIO). Any recipient of this document wanting additional information or to effect any transaction in Indian securities or financial instrument mentioned herein must do so by contacting a representative of ABN AMRO Asia Equities (India) Limited.

Italy: Persons in Italy requiring further information should contact ABN AMRO Bank N.V. Milan Branch.

Japan: This report is being distributed in Japan by ABN AMRO Securities Japan Ltd to institutional investors only.

Malaysia: ABN AMRO research, except for economics and FX research, is not for distribution or transmission into Malaysia.

New Zealand: This document is distributed in New Zealand by ABN AMRO NZ Limited an accredited NZX Firm.

Russia: The Russian securities market is associated with several substantial risks, legal, economic and political, and high volatility. There is a relatively high measure of legal uncertainty concerning rights, duties and legal remedies in the Russian Federation. Russian laws and regulations governing investments in securities markets may not be sufficiently developed or may be subject to inconsistent or arbitrary interpretation or application. Russian securities are often not issued in physical form and registration of ownership may not be subject to a centralised system. Registration of ownership of certain types of securities may not be subject to standardised procedures and may even be effected on an ad hoc basis. The value of investments in Russian securities may be affected by fluctuations in available currency rates and exchange control regulations.

Singapore: Any report referring to equity securities is distributed in Singapore by ABN AMRO Asia Securities (Singapore) Pte Limited (RCB Regn No. 198703346M) to clients who fall within the description of persons in Regulation 49 of the Securities and Futures (Licensing and Conduct of Business) Regulations and Regulations 34 and 35 of the Financial Advisers Regulations. Any report referring to non-equity securities is distributed in Singapore by ABN AMRO Bank NV (Singapore Branch) Limited to clients who fall within the description of persons in Regulations 34 and 35 of the Financial Advisers Regulations. Investors should note that this material was prepared for accredited investors only. Recipients who do not fall within the description of persons under Regulation 49 of the Securities and Futures (Licensing and Conduct of Business) Regulations or Regulations 34 and 35 of the Financial Advisers Regulations should seek the advice of their independent financial advisor prior to taking any investment decision based on this document or for any necessary explanation of its contents.

Sweden: ABN AMRO Bank N.V. is authorised and regulated in the Netherlands by De Nederlandsche Bank. In addition, ABN AMRO Bank N.V., Stockholm Branch is subject to local supervision by the Swedish Financial Supervisory Authority. ABN AMRO has adopted rules to ensure the integrity and independence of research analysts and the research function, as well as to identify, manage, avoid or make public actual or potential conflict of interests relating to analysts or ABN AMRO.

Thailand: Pursuant to an agreement with Asia Plus Securities Public Company Limited (APS), reports on Thai securities published out of Thailand are prepared by APS but distributed outside Thailand by ABN AMRO Bank NV and affiliated companies. Responsibility for the views and accuracy expressed in such documents belongs to APS.

United Kingdom: All research is distributed by ABN AMRO Bank NV, London Branch, which is authorised by De Nederlandsche Bank and by the Financial Services Authority; and regulated by the Financial Services Authority for the conduct of UK business. The investments and services contained herein are not available to private customers in the United Kingdom.

United States: Except for any documents relating to foreign exchange, FX or global FX, distribution of this document in the United States or to US persons is intended to be solely to major institutional investors as defined in Rule 15a-6(a)(2) under the US Securities Act of 1934. All US persons that receive this document by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities. Any US recipient of this document wanting additional information or to effect any transaction in any security or financial instrument mentioned herein, must do so by contacting a registered representative of ABN AMRO Incorporated, Park Avenue Plaza, 55 East 52nd Street, New York, N.Y. 10055, US, tel + 1 212 409 1000, fax +1 212 409 5222.

- Material means all research information contained in any form including but not limited to hard copy, electronic form, presentations, e-mail, SMS or WAP.

The research analyst or analysts responsible for the content of this research report certify that: (1) the views expressed and attributed to the research analyst or analysts in the research report accurately reflect their personal opinion(s) about the subject securities and issuers and/or other subject matter as appropriate; and, (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views contained in this research report. On a general basis, the efficacy of recommendations is a factor in the performance appraisals of analysts.

For a discussion of the valuation methodologies used to derive our price targets and the risks that could impede their achievement, please refer to our latest published research on those stocks at www.abnamroresearch.com.

Disclosures regarding companies covered by ABN AMRO group can be found on ABN AMRO's research website at www.abnamroresearch.com.

ABN AMRO's policy on managing research conflicts of interest can be found at <https://www.abnamroresearch.com/Disclosure/Disclosure.AspX?MI=5>.

Should you require additional information please contact the relevant ABN AMRO research team or the author(s) of this report.